Get the Stockscreener App
4.89
5.60%
-0.29
After Hours:
4.89
Zura Bio Ltd stock is traded at $4.89, with a volume of 1.45M.
It is down -5.60% in the last 24 hours and down -19.31% over the past month.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
See More
Previous Close:
$5.18
Open:
$5.17
24h Volume:
1.45M
Relative Volume:
2.55
Market Cap:
$463.97M
Revenue:
-
Net Income/Loss:
$-68.65M
P/E Ratio:
-4.103
EPS:
-1.1918
Net Cash Flow:
$-64.93M
1W Performance:
-2.40%
1M Performance:
-19.31%
6M Performance:
+40.52%
1Y Performance:
+300.82%
1-Day Range:
$4.73
$5.2081
1-Week Range:
$4.73
$5.50
52-Week Range:
$0.98
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
4.89 | 491.48M | 0 | -68.65M | -64.93M | -1.1918 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Wedbush | Outperform |
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) — 4.7% stake - Stock Titan
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio | DEF 14A: Definitive information statements - Moomoo
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
[DEF 14A] Zura Bio Ltd Definitive Proxy Statement - Stock Titan
ZURA News | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio Limited 8-K Filing Details April 2026 – Separation Agreement, Company Information, and SEC Compliance - Minichart
Zura Bio LtdEric Hyllengren separated from Zura Bio Limited as CFO on April 20, 2026 - marketscreener.com
Zura Bio : Corporate Overview April 2026 (d9fec3) - marketscreener.com
Zura Bio Limited Announces CFO Changes, Effective April 20, 2026 - marketscreener.com
[8-K] Zura Bio Ltd Reports Material Event - Stock Titan
Jessica Chen - White & Case LLP
One Zura Bio Insider Raised Their Stake In The Previous Year - Yahoo Finance
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering - Benzinga
JATT Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
JATT Technical Analysis & Stock Price Forecast - Intellectia AI
JATT PE Ratio & Valuation, Is JATT Overvalued - Intellectia AI
JATT Forecast — Price Prediction for 2026. Should I Buy JATT? - Intellectia AI
Zura Bio Ltd stock (KYG989201089): Is its immunology pipeline strong enough to unlock biotech upside - AD HOC NEWS
Zura Bio Ltd stock: Why analysts see massive upside potential - AD HOC NEWS
Zura Bio (NASDAQ:ZURA) Shares Down 6.5%Here's What Happened - MarketBeat
Biotechnology executive pays $15 million for Pinecrest home (Photos) - The Business Journals
Zura Bio (ZURA) CTO awarded 263,000 share options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) officer receives 340,900 options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) CFO receives stock options for 340,900 shares at $6.03 - Stock Titan
Zura Bio grants 425,700 options to legal chief | ZURA Insider Trading - Stock Titan
Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares - Stock Titan
Chipmakers Recap: Is Zura Bio Limited a momentum stock2026 Highlights & Verified Swing Trading Watchlist - baoquankhu1.vn
Market Fear: Will Zura Bio Limited benefit from rising consumer demandChart Signals & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - tradingview.com
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $15.00 - Defense World
ZURA: Oppenheimer Lowers Price Target, Maintains Outperform Rati - GuruFocus
Zura Bio (NASDAQ:ZURA) Given New $15.00 Price Target at Oppenheimer - MarketBeat
Zura Bio Ltd expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zura Bio Ltd Aktie surges on positive Phase 2 data for autoimmune drug candidate - AD HOC NEWS
Zura Bio Limited 2025 Annual Report: Clinical-Stage Biotech Advancing Novel Autoimmune Therapies and Key Risk Factors - Minichart
Zura Bio (NASDAQ: ZURA) outlines autoimmune pipeline, Phase 2 timelines - Stock Titan
Zura Bio GAAP EPS of -$1.06 misses by $0.31 - One News Page
Zura Bio 10-K: $0.0M Revenue, $(X.XX) EPS on reported net loss - TradingView
2025 financial update released as Zura Bio outlines new corporate developments - Traders Union
Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials - Stock Titan
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates - ChartMill
Ajay Nirula Net Worth (2026) - GuruFocus
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February - MarketBeat
Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC - MarketBeat
ZURA Technical Analysis & Stock Price Forecast - Intellectia AI
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):